Skip to main content

Table 3 Imaging parameters in healthy controls and type 2 diabetic patients

From: Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine

 

Controls (n = 10)

T2DM patients (n = 26)

P

CMR

 LVEDV, mL

202 ± 36

209 ± 70

0.79

 LVESV, mL

83 ± 18

117 ± 75

0.19

 LV mass, g

123 ± 25

116 ± 27

0.51

 LVEF, %

59 ± 4

47 ± 13

<0.01

 DCE, g

0

6.3 (0–11.3)

<0.01

PET

 MBF, rest, mL−1 min−1 g−1

0.75 ± 0.07

0.86 ± 0.19

0.02

 MBF, rest, corrected for RPP, mL min−1 g−1

1.22 ± 0.1

1.11 ± 0.4

0.20

 MBF, stress, mL min−1 g−1

2.64 ± 0.28

2.05 ± 0.65

<0.01

 CFR

3.54 ± 0.54

2.43 ± 0.79

<0.01

 CFR, corrected for RPP, mmHg min−1

2.20 ± 0.35

1.97 ± 0.74

0.56

 External work, Joule

1.26 ± 0.26

1.00 ± 0.31

0.04

 MVO2, mL g−1 min−1

0.09 ± 0.01

0.08 ± 0.01

0.23

 Myocardial efficiency, %

32 ± 6

35 ± 9

0.39

  1. Data are mean ± SD or median (interquartile range)
  2. T2DM type 2 diabetes mellitus, CMR cardiac magnetic resonance, LVEDV left ventricular enddiastolic volume, LVESV left ventricular endsystolic volume, LVEF left ventricular ejection fraction, DCE delayed contrast enhancement, PET positron emission tomography, MBF myocardial blood flow, RPP rate pressure product, CFR coronary flow reserve, MVO 2 myocardial oxygen consumption